Bob,
Yes, it is a bit frustrating to locate the PA in Grants.gov (or using the
NIH Guide on nih.gov) if you just use the key word 'R21'.  I had to find it
using 'Parent R21', and even then it displayed more than one listing.
However, PA-06-181 is for 'investigator-initiated' R21s for the NIH
Institutes that participate in the program and are listed at the beginning
of the PA.  There will be many other PAs that use the R21 funding mechanism
but are geared to specific subjects and/or timeframes.

There is also a 'Parent' R03, which is PA-06-180.  NIH will post a generic,
parent R01 closer to electronic submission of R01s in February '07.

Hope this helps.
Regards to all,
Steve Hunter
Legacy Research
Portland, OR

-----Original Message-----
From: Research Administration List [mailto:xxxxxx@HRINET.ORG]On Behalf
Of Robert Beattie
Sent: Wednesday, April 26, 2006 12:54 PM
To: xxxxxx@HRINET.ORG
Subject: Re: [RESADM-L] NIH R21 CFDA # or Funding opportunity #

Maybe someone with a better understanding, than I have, of how NIH
announcements work  can help me understand the difference between the
various R21 announcements.

This is the program with the link below, that Steve points to --
"Parent R21"
PA-06-181: NIH Exploratory/Developmental Research Grant Program
(Parent R21)

Yet if one does a Keyword Search in Grants.gov, using R21, a very
long list shows up.  One item on the list
for example is -
PA-06-150: Pilot and Feasibility Program in Hematologic Diseases (R21)

There are many others.  Are these specific programs not the "NIH
investigator-initiated R21" that Pam was asking about?

I thought we might be able to download "the" R21 (and "the" R03 and
R33) form to our server and enter the standard institution data.
Then people would download the file from our site.  There are,
however, so many different programs I do no know how we can do that.

Thanks for the group help.

Bob
xxxxxx@umich.edu

On Apr 26, 2006, at 3:36 PM, Smiley, Rick wrote:

http://grants.nih.gov/grants/guide/pa-files/PA-06-181.html

Rick Smiley
Grant & Contract Officer

From: Research Administration List [mailto:xxxxxx@HRINET.ORG] On
Behalf Of Plotkin, Pamela T.
Sent: Wednesday, April 26, 2006 2:42 PM
To: xxxxxx@HRINET.ORG
Subject: [RESADM-L] NIH R21 CFDA # or Funding opportunity #

My apologies to the list if this question has already been answered.
I have been off the list for about 6 weeks now because of an internal
IT problem that prevented me from receiving email messages from resadm-l

Can anyone tell me what is the CFDA # or the funding opportunity #
for the NIH investigator-initiated R21?

Nice to be connected again. I learn so much from y’all. Thanks!!!!

Pam

Pamela Plotkin, Ph.D.

Assistant Vice President for Research and

Director of Sponsored Programs

East Tennessee State University

Office of Research and Sponsored Programs

Box 70565

Johnson City, TN 37614-1707

phone: 423-439-6000

fax: 423-439-6050

email:

http://www.etsu.edu/research

====================================================================== I
nstructions on how to use the RESADM-L Mailing List, including
subscription information and a web-searchable archive, are available
via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

====================================================================== I
nstructions on how to use the RESADM-L Mailing List, including
subscription information and a web-searchable archive, are available
via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================

IMPORTANT NOTICE:  This communication, including any attachment, contains
information that may be confidential or privileged, and is intended solely
for the entity or individual to whom it is addressed.  If you are not the
intended recipient, you should contact the sender and delete the message.
Any unauthorized disclosure, copying, or distribution of this message is
strictly prohibited.  Nothing in this email, including any attachment, is
intended to be a legally binding signature.

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================